Baseline patient characteristics
| SDB | No SDB | p-value | |
| Subjects n | 29 | 25 | |
| Age years | 55±10 | 53±10 | 0.563 |
| BMI kg·m-2 | 30±4 | 27±3 | 0.002 |
| Male | 26 (90) | 19 (76) | 0.179 |
| Hypertension | 16 (55) | 15 (60) | 0.721 |
| Diabetes mellitus | 5 (17) | 3 (12) | 0.589 |
| Hypercholesterolaemia | 9 (31) | 10 (40) | 0.492 |
| Smoking | 19 (66) | 22 (88) | 0.054 |
| STEMI | 24 (83) | 20 (80) | 0.856 |
| Target of primary coronary occlusion | 0.363 | ||
| LAD | 14 (48) | 9 (36) | |
| Non-LAD | 15 (52) | 16 (64) | |
| Grade 0 TIMI flow before PCI | 25 (86) | 19 (76) | 0.340 |
| Grade 3 TIMI flow after PCI | 27 (93) | 24 (96) | 0.643 |
| Killip classification | 0.715 | ||
| Class I | 22 (76) | 20 (80) | |
| Class II | 7 (24) | 5 (20) | |
| Heart rate beats·min−1 | 76±17 | 71±17 | 0.300 |
| Systolic blood pressure mmHg | 130±20 | 129±23 | 0.875 |
| Diastolic blood pressure mmHg | 78±12 | 80±13 | 0.580 |
| LVEF after PCI % | 45±9 | 49±8 | 0.057 |
| LVESV after PCI mL | 97±31 | 77±22 | 0.010 |
| Peak CK U·L−1 | 2023±1243 | 1475±1271 | 0.123 |
| Medication after PCI | |||
| Aspirin | 29 (100) | 25 (100) | 1.0 |
| ADP receptor inhibitors | 29 (100) | 25 (100) | 1.0 |
| β-blockers | 27 (93) | 25 (100) | 0.181 |
| ACE inhibitor/ARB | 29 (100) | 25 (100) | 1.0 |
| Statins | 27 (93) | 25 (100) | 0.181 |
| Medication at 12 weeks | |||
| Aspirin | 26 (90) | 24 (96) | 0.384 |
| ADP receptor inhibitors | 22 (76) | 22 (88) | 0.261 |
| β-blockers | 25 (86) | 22 (88) | 0.848 |
| ACE inhibitor/ARB | 27 (93) | 21 (84) | 0.297 |
| Statins | 27 (93) | 24 (96) | 0.651 |
Data are presented as mean±sd or n (%), unless otherwise stated. SDB: sleep disordered breathing; BMI: body mass index; STEMI: ST-segment elevation myocardial infarction; LAD: left anterior descending; TIMI: thrombolysis in myocardial infarction; PCI: percutaneous coronary intervention; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; CK: creatinine kinase; ADP: adenosine diphosphate; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker.